Citations

Mayo Clinic

Showing 10 of 108572 citations.

Faculty Opinions recommendation of Acute exacerbations complicating interstitial lung disease.
Ryu, Jay H.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718496173.793524897 Get It

Faculty Opinions recommendation of Histological diagnosis of interstitial lung diseases by cryo-transbronchial biopsy.
Ryu, Jay H.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718358707.793524893 Get It

Faculty Opinions recommendation of Chronic Hypersensitivity Pneumonitis With a Usual Interstitial Pneumonia-Like Pattern: Correlation Between Histopathologic and Clinical Findings.
Ryu, Jay H.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726113335.793524889 Get It

Faculty Opinions recommendation of An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
Ryu, Jay H.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725624039.793524888 Get It

Faculty Opinions recommendation of Unclassifiable interstitial lung disease: A review.
Ryu, Jay H.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725548102.793524887 Get It

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis
Arceci, R.J., Allen, Carl E. , Jacobsen, Eric D. , Whitlock, James A. , Vassallo, Robert , Morris, Shannon R., Portnoy, Alison, Reedy, Beth Ann, Smith, Deborah A. , Noble, Robert, Murnane, Amy A., Cornfeld, Mark, Heaney, Mark , McClain, Kenneth L. , Vaiselbuh, Sarah R., Dunkel, Ira J. , Rodríguez‐Galindo, Carlos , Vassallo, Robert , McClain, Kenneth L , Allen, Carl E

Pediatric Blood & Cancer | November 2, 2016 | Volume: 64 | Issue: 5 | Pages: No page available

10.1002/pbc.26325 | PMID 27804235 Get It

AbstractBackgroundLangerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and proliferation of dendritic cells, and is also often upregulated in hematopoietic malignancies. A clinical response in an adult patient with LCH participating in the first‐in‐human trial of afuresertib prompted this prospective trial.ProcedureThe population in the current study included treatment‐naïve (n = 7) and recurrent/refractory patients with LCH (n = 10), who received oral afuresertib (125 mg). The majority of patients were treated for > 24 weeks, with four patients receiving treatment for > 48 weeks.ResultsPharmacokinetic analysis showed similar exposures in previously reported patients with other hematologic malignancies. Primary drug‐related toxicities included Grade 1/2 nausea, diarrhea, dyspepsia, and vomiting. Grade 3 toxicities included fatigue, diarrhea, and pain (one of each). Another severe adverse event involved soft tissue necrosis. The overall response rate in evaluable subjects was 33% in treatment‐naïve patients and 28% in patients with recurrent/refractory disease, which did not meet the predefined Bayesian criteria for efficacy.ConclusionAfuresertib has clinical activity in some patients with newly diagnosed and advanced LCH.
Double Aortic Arch Causing Severe Tracheal Compression
Barbara, David W. , Patch, Richard K. , Pochettino, Alberto , Broski, Stephen M.

Anesthesiology | November 2, 2016 | Volume: 126 | Issue: 2 | Pages: 326-326

10.1097/aln.0000000000001439 | PMID 27811486 Get It

The Development and Evaluation of a Novel Instrument Assessing Residents’ Discharge Summaries
Hommos, Musab S. , Kuperman, Ethan , Kamath, Aparna, Kreiter, Clarence D. , Hommos, Musab S

Academic Medicine | November 2, 2016 | Volume: 92 | Issue: 4 | Pages: 550-555

10.1097/acm.0000000000001450 | PMID 27805951 Get It

Purpose To develop and determine the reliability of a novel measurement instrument assessing the quality of residents’ discharge summaries. Method In 2014, the authors created a discharge summary evaluation instrument based on consensus recommendations from national regulatory bodies and input from primary care providers at their institution. After a brief pilot, they used the instrument to evaluate discharge summaries written by first-year internal medicine residents (n = 24) at a single U.S. teaching hospital during the 2013–2014 academic year. They conducted a generalizability study to determine the reliability of the instrument and a series of decision studies to determine the number of discharge summaries and raters needed to achieve a reliable evaluation score. Results The generalizability study demonstrated that 37% of the variance reflected residents’ ability to generate an adequate discharge summary (true score variance). The decision studies estimated that the mean score from six discharge summary reviews completed by a unique rater for each review would yield a reliability coefficient of 0.75. Because of high interrater reliability, multiple raters per discharge summary would not significantly enhance the reliability of the mean rating. Conclusions This evaluation instrument reliably measured residents’ performance writing discharge summaries. A single rating of six discharge summaries can achieve a reliable mean evaluation score. Using this instrument is feasible even for programs with a limited number of inpatient encounters and a small pool of faculty preceptors.
Role of the overall treatment time of radiotherapy with 10 × 3 Gy for outcomes in patients with metastatic spinal cord compression
Rades, Dirk , Conde-Moreno, Antonio J. , Cacicedo, Jon , Metz, Michaela, Veninga, Theo, Rudat, Volker , Schild, Steven E. , Janssen, Stefan , Šegedin, Barbara

Journal of Medical Imaging and Radiation Oncology | November 2, 2016 | Volume: 61 | Issue: 3 | Pages: 388-393

10.1111/1754-9485.12553 | PMID 27804231 Get It

AbstractIntroductionRadiotherapy alone still is the most commonly delivered treatment modality for metastatic spinal cord compression (MSCC). MSCC is an emergency situation, which requires treatment as soon as possible. When radiotherapy is performed with the most commonly used approach 10 × 3 Gy (30 Gy in 10 fractions) over 2 weeks, the question has been asked whether an overall treatment time (OTT) of 14–15 days including two weekends without irradiation leads to worse outcomes than OTT of 12 days (beginning of radiotherapy on a Monday resulting in only one weekend break)?MethodsA total of 412 patients with MSCC were included in this retrospective study. Ninety‐two patients receiving 10 × 3 Gy over 12 days were compared to 320 patients with an OTT of 14–15 days. Ten additional factors were investigated.ResultsOn multivariate analysis, functional outcome was associated with tumour type (P < 0.001), time developing motor deficits (P < 0.001), ambulatory status (P = 0.018) and performance score (P < 0.001); OTT had no significant impact (P = 0.40). On univariate analysis of local control of MSCC (freedom from recurrence in irradiated spinal parts), no factor was significant including OTT (P = 0.66). On multivariate analysis, visceral metastases (P < 0.001), tumour type (P < 0.001), time developing motor deficits (P < 0.001), ambulatory status (P < 0.001) and performance score (P < 0.001) were associated with survival, OTT not even on univariate analysis (P = 0.55).ConclusionsSince an OTT of 14–15 days had no negative impact on outcomes compared to 12 days, compensation in form of an additional radiation fraction or continuation of radiotherapy during weekends is not required, if radiotherapy cannot be started on a Monday.
Clinical Impact of Amyloid Positron Emission Tomography—Is It Worth the Cost?
Caselli, Richard J. , Woodruff, Bryan K.

JAMA Neurology | November 1, 2016 | Volume: 73 | Issue: 12 | Pages: 1396

10.1001/jamaneurol.2016.3792 | PMID 27802483 Get It